Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerotic Inflammation
FY 2025-26
Summary
Cardiovascular disease is a leading cause of death in Canada, primarily due to atherosclerosis from cholesterol buildup. PCSK9, a serine protease, is known for promoting degradation of LDL receptors (LDLRs) that internalize plaque-forming cholesterol from the bloodstream. Beyond their lipid-lowering effects, PCSK9 inhibitor therapies have demonstrated anti-inflammatory properties, revealing PCSK9’s pro-inflammatory role. Within plaques, PCSK9 is expressed in macrophages, endothelial cells, and smooth muscle cells, where it upregulates pro-inflammatory cytokines like interleukin-1B (IL-1B) and IL-6. This inflammation is implicated in plaque destabilization, risking thrombotic myocardial infarction. Furthermore, PCSK9 has distinct subtypes, including its furin-cleaved form (f-PCSK9), whose differences compared to wild-type (WT) PCSK9 (uncleaved form) remain underexplored. Importantly, by blocking the PCSK9-LDLR binding interface, PCSK9 inhibitors also prevent furin cleavage of PCSK9. Notably, their anti-inflammatory effects may be due to preventing f-PCSK9 formation. Yet no studies distinguish the relative contributions of f-PCSK9 and WT to the observed pro-inflammatory effects. Hence, my novel hypothesis: f-PCSK9 induces a stronger pro-inflammatory cytokine response than WT due to preferential uptake in macrophages. Thus, I treat THP-1 macrophages with f-PCSK9 and WT. Thereafter, qRT-PCR demonstrates higher pro-inflammatory cytokine mRNA with f-PCSK9 treatment, consistent with Western blot showing preferential uptake of the f-PCSK9 variant. Such inflammation drives detrimental atherosclerosis despite cholesterol-lowering drugs. As such, my delineation of the functional differences between f-PCSK9 and WT is vital for designing variant-specific, life-saving interventions.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572544
Name
Sivasathiyanathan Soumiya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerotic Inflammation
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Atherosclerosis; Furin; Inflammation; Macrophage; Pcsk9
Abstract
Cardiovascular disease is a leading cause of death in Canada, primarily due to atherosclerosis from cholesterol buildup. PCSK9, a serine protease, is known for promoting degradation of LDL receptors (LDLRs) that internalize plaque-forming cholesterol from the bloodstream. Beyond their lipid-lowering effects, PCSK9 inhibitor therapies have demonstrated anti-inflammatory properties, revealing PCSK9’s pro-inflammatory role. Within plaques, PCSK9 is expressed in macrophages, endothelial cells, and smooth muscle cells, where it upregulates pro-inflammatory cytokines like interleukin-1B (IL-1B) and IL-6. This inflammation is implicated in plaque destabilization, risking thrombotic myocardial infarction. Furthermore, PCSK9 has distinct subtypes, including its furin-cleaved form (f-PCSK9), whose differences compared to wild-type (WT) PCSK9 (uncleaved form) remain underexplored. Importantly, by blocking the PCSK9-LDLR binding interface, PCSK9 inhibitors also prevent furin cleavage of PCSK9. Notably, their anti-inflammatory effects may be due to preventing f-PCSK9 formation. Yet no studies distinguish the relative contributions of f-PCSK9 and WT to the observed pro-inflammatory effects. Hence, my novel hypothesis: f-PCSK9 induces a stronger pro-inflammatory cytokine response than WT due to preferential uptake in macrophages. Thus, I treat THP-1 macrophages with f-PCSK9 and WT. Thereafter, qRT-PCR demonstrates higher pro-inflammatory cytokine mRNA with f-PCSK9 treatment, consistent with Western blot showing preferential uptake of the f-PCSK9 variant. Such inflammation drives detrimental atherosclerosis despite cholesterol-lowering drugs. As such, my delineation of the functional differences between f-PCSK9 and WT is vital for designing variant-specific, life-saving interventions.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sivasathiyanathan, Soumiya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~